- Home
- VSCO vs ETNB Comparison
VSCO vs ETNB Comparison
Compare VSCO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- ETNB
- Stock Information
- Founded
- VSCO 1977
- ETNB 2018
- Country
- VSCO United States
- ETNB United States
- Employees
- VSCO N/A
- ETNB N/A
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- VSCO Consumer Discretionary
- ETNB Health Care
- Exchange
- VSCO Nasdaq
- ETNB Nasdaq
- Market Cap
- VSCO 1.6B
- ETNB 1.5B
- IPO Year
- VSCO N/A
- ETNB 2019
- Fundamental
- Price
- VSCO $23.02
- ETNB $9.03
- Analyst Decision
- VSCO Hold
- ETNB Strong Buy
- Analyst Count
- VSCO 12
- ETNB 9
- Target Price
- VSCO $25.33
- ETNB $26.63
- AVG Volume (30 Days)
- VSCO 3.3M
- ETNB 1.6M
- Earning Date
- VSCO 08-28-2025
- ETNB 08-07-2025
- Dividend Yield
- VSCO N/A
- ETNB N/A
- EPS Growth
- VSCO 6.85
- ETNB N/A
- EPS
- VSCO 1.86
- ETNB N/A
- Revenue
- VSCO $6,265,451,000.00
- ETNB N/A
- Revenue This Year
- VSCO $2.39
- ETNB N/A
- Revenue Next Year
- VSCO $2.05
- ETNB N/A
- P/E Ratio
- VSCO $12.39
- ETNB N/A
- Revenue Growth
- VSCO 2.29
- ETNB N/A
- 52 Week Low
- VSCO $13.76
- ETNB $4.16
- 52 Week High
- VSCO $48.73
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- VSCO 60.72
- ETNB 43.91
- Support Level
- VSCO $21.91
- ETNB $9.07
- Resistance Level
- VSCO $25.47
- ETNB $9.62
- Average True Range (ATR)
- VSCO 1.11
- ETNB 0.42
- MACD
- VSCO 0.04
- ETNB 0.03
- Stochastic Oscillator
- VSCO 42.22
- ETNB 31.63
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a retailer of women's intimate and other apparel and beauty products marketed under the Victoria's Secret, PINK, and Adore Me brand names. It also includes the merchandise sourcing and production function serving the Company and its international partners. The Company operates as a single segment designed to serve customers seamlessly through stores and online channels.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).